Biogen and Eisai said the FDA delayed its decision on subcutaneous Leqembi, pushing the review date to August 24. The original decision timing was later this month, extending uncertainty for a therapy whose uptake depends on route convenience and reimbursement dynamics. At the same time, Artiva Therapeutics raised $300 million, according to the same update set. The funding underscores continued capital access for late-stage neurologic and immunology-adjacent programs even as regulatory timelines shift. Pharvaris also priced an offering in the update, adding to a picture of active financing across specialty biotech as companies manage regulatory calendar risk.